counter-ion comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Typical purity | 95% or higher | By reversed-phase HPLC area |
| Identity method | Electrospray mass spectrometry | Confirms molecular mass |
| Purity method | Reversed-phase HPLC | Detection near 214 nm |
| Primary degradation | Methionine oxidation | Sulfoxide product, +16 Da |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw |
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
After failing to secure a major label contract, Danniels founded the independent Moon Records and negotiated a distribution deal with London Records for a single and one full-length album. For their debut release, the band selected a cover of Buddy Holly's "Not Fade Away" as it had become a crowd favourite, with "You Can't Fight It", an original song, on the B-side. Released in September 1973, the single peaked at No. 88 on the national RPM Top Singles chart. The launch coincided with the band's first major high-profile engagement, opening for the New York Dolls in Toronto.
== United States usage == The Congress of the United States customarily adjourns a session sine die on the morning of January 3, immediately before the next session holds its constitutionally mandated first meeting. It can also adjourn sine die at other times through a concurrent resolution that allows the Speaker of the House and Senate Majority Leader to resume the session. State legislatures follow suit and mark adjournment sine die with a ceremony, such as the Connecticut General Assembly wherein, on the final day of the legislative session, the House and Senate meet in a joint convention, and the Secretary of the State recites "Oyez, Oyez, Oyez", pounds the gavel, and declares the legislature adjourned sine die. In the Florida Legislature, the sergeants-at-arms of the Florida Senate and the Florida House of Representatives step outside their chambers each holding a handkerchief. When they meet in between the chambers, they both drop the handkerchiefs, signifying the end of the legislative session.
=== Efficacy === As of 2007 there were not enough good-quality trials of herbal therapies to allow their effectiveness to be determined. A high percentage of relevant studies on traditional Chinese medicine are in Chinese databases. Fifty percent of systematic reviews on TCM did not search Chinese databases, which could lead to a bias in the results. Many systematic reviews of TCM interventions published in Chinese journals are incomplete, some contained errors or were misleading. The herbs recommended by traditional Chinese practitioners in the US are unregulated.
Umami peptides are a family of small to medium length polypeptides found in a variety of savoury foods, which impart an umami taste. They are best known from Asian condiments and foods such as soy sauce, fish sauce, oyster sauce, and miso, but are also found in a diverse range of other foods including cheese, stewed or preserved meat products, and Bolete mushrooms. One of the best characterised umami peptides is beefy meaty peptide, originally isolated from beef soup, an eight amino acid peptide with the sequence Lys-Gly-Asp-Glu-Glu-Ser-Leu-Ala which is thought to interact with the T1R1/T1R3 taste receptor complex. There are dozens if not hundreds of umami peptides known, most of which have been little studied in isolation as they typically occur in complex mixtures, which can vary significantly between different foods, brands, and even different batches made the same way. Not all peptides isolated from such mixtures have umami flavour, with some closely related peptides tasting sweet, sour, salty, bitter or kokumi, and often a change in only a single amino acid can be enough to change the flavour entirely. However, the majority of peptides isolated from fermented foods or cooked or preserved meat products tend to have an umami flavour, with trace amounts of peptides with other flavours contributing to the overall flavour profile of the food.
Retiform hemangioendothelioma (hobnail hemangioendothelioma) Schwannoma (acoustic neuroma, neurilemmoma, neurinoma, neurolemmoma, Schwann cell tumor) Solitary angiokeratoma Solitary cutaneous leiomyoma Solitary mastocytoma Solitary neurofibroma (plexiform neurofibroma, solitary nerve sheath tumor, sporadic neurofibroma) Spider angioma (nevus araneus, spider telangiectasia, spider nevus, vascular spider) Spindle cell hemangioendothelioma (spindle cell hemangioma) Spindle cell lipoma Sternal cleft Subungual exostosis Superficial acral fibromyxoma Systemic mastocytosis Targetoid hemosiderotic hemangioma (hobnail hemangioma) Telangiectasia Telangiectasia macularis eruptiva perstans Teratoma Tufted angioma (acquired tufted angioma, angioblastoma, angioblastoma of Nakagawa, hypertrophic hemangioma, progressive capillary hemangioma, tufted hemangioma) Umbilical granuloma Universal angiomatosis (generalized telangiectasia) Urticaria pigmentosa (childhood type of generalized eruption of cutaneous mastocytosis) Venous lake (phlebectasis) Wildervanck syndrome Xanthelasmoidal mastocytosis Zosteriform metastasis
Sources: en.wikipedia.org
It was agreed to by a previous Progressive Conservative government after DynaLIFE appealed AHS's contractual arrangement for provision of lab services with Sonic Healthcare, an Australian company. Sonic would have provided these services in Edmonton and northern Alberta starting in October 2014, but the contract was cancelled through DynaLIFE's successful appeal. The provincial government announced on December 5, 2022, that the public Alberta Precision Laboratories (APL) was going to be replaced by the private, for-profit DynaLIFE in providing community lab services in Alberta's large municipalities. By early January 2023, wait times had increased for blood tests that used to be routine and rapid. A University of Calgary assistant professor in health law questioned DynaLIFE's cut backs on "staffing or hours".
== Elected or appointed female chief executives == This list includes women who were appointed by a governing committee or parliament where heads of state or government are not directly elected by citizens. The list does not include women chosen by a hereditary monarch. Interim heads of state or government are listed in italics.
MRI requires a magnetic field that is both strong and uniform to a few parts per million across the scan volume. The field strength of the magnet is measured in teslas – and while the majority of systems operate at 1.5 T, commercial systems are available between 0.2 and 7 T. 3T MRI systems, also called 3 Tesla MRIs, have stronger magnets than 1.5 systems and are considered better for images of organs and soft tissue. Whole-body MRI systems for research applications operate in e.g. 9.4T, 10.5T, 11.7T. Even higher field whole-body MRI systems e.g. 14 T and beyond are in conceptual proposal or in engineering design. Most clinical magnets are superconducting magnets, which require liquid helium to keep them at low temperatures. Lower field strengths can be achieved with permanent magnets, which are often used in "open" MRI scanners for claustrophobic patients. Lower field strengths are also used in a portable MRI scanner approved by the FDA in 2020. Recently, MRI has been demonstrated also at ultra-low fields, i.e., in the microtesla-to-millitesla range, where sufficient signal quality is made possible by prepolarization (on the order of 10–100 mT) and by measuring the Larmor precession fields at about 100 microtesla with highly sensitive superconducting quantum interference devices (SQUIDs).
NH3 + 5-glutamyl-D-glutamyl-peptide The 3 substrates of this enzyme are L-glutamine, D-glutamine, and D-glutamyl-peptide, whereas its two products are NH3 and 5-glutamyl-D-glutamyl-peptide. This enzyme belongs to the family of transferases, specifically the aminoacyltransferases. The systematic name of this enzyme class is glutamine:D-glutamyl-peptide 5-glutamyltransferase. Other names in common use include D-glutamyl transpeptidase, and D-gamma-glutamyl transpeptidase. This enzyme participates in d-glutamine and d-glutamate metabolism.
== Pseudo-Amino Acid Composition (PseAAC) model == The primary weakness of the discrete model that relies on the amino acid composition (AAC) is that the information on the frequencies of each amino acid from the sample alone involves a loss of sequence-order information, or information obtained by the order of the amino acid residues. To avoid this information loss, the concept of PseAAC (pseudo amino acid composition) was proposed. Under this new model, the first 20 discrete factors represent amino acid frequencies are retained, but additional discrete factors are included that also ascertain information about sequence order. The sequence order information is represented by what are called "pseudo components". The number of additional components, beyond the first 20 frequencies, is called λ (or upper-case Λ), and so 20+λ components are included in the model. The upper limit for λ is one less than the length of the shortest protein sample in the dataset. The total number of components (20+λ) may be denoted Ω. Any additional factors can be incorporated so long as they, in some way, obtain or represent information about the sequence-order. Typically, these are a series of rank-different correlation factors along the protein chain. The additional factors are a series of rank-different correlation factors along a protein chain, but they can also be any combinations of other factors so long as they can reflect some sorts of sequence-order effects one way or the other.
Sources: en.wikipedia.org
KGOP01 (H-Dmt-d-Arg-Aba-β-Ala-NH2) is a synthetic peptide derivative which acts as a potent agonist of opioid receptors and has analgesic effects. It was originally derived from modification of dermorphin, a naturally occurring opioid peptide secreted by some species of South American frogs. While numerous opioid peptides are known and widely used in scientific research, such as DAMGO and DADLE, these are rapidly metabolised in the body and fail to cross the blood-brain barrier, and so do not produce centrally mediated analgesic effects. KGOP01 on the other hand contains several unnatural amino acids and is both metabolically stable and able to enter the brain, resulting in potent analgesic effects in animal studies. Because it is a peptide, it can be readily hybridised with other peptide ligands and so has been widely used to produce hybrid compounds combining opioid activity with activity at receptors for neuropeptides such as nociceptin, neurokinin, neurotensin and neuropeptide FF, which may lead to the development of improved opioid analgesics with reduced side effects.
=== Broader negative impact on science === Just as the impact factor has attracted criticism for various immediate problems associated with its application, so has there also been criticism that its application undermines the broader process of science. Research has indicated that bibliometrics figures, particularly the impact factor, decrease the quality of peer review an article receives, cause a reluctance to share data, decrease the quality of articles, and a reduce the scope of publishable research. "For many researchers the only research questions and projects that appear viable are those that can meet the demand of scoring well in terms of metric performance indicators—and chiefly the journal impact factor." Furthermore, the process of publication and science is slowed down—authors automatically try to publish with the journals with the highest impact factor—"as editors and reviewers are tasked with reviewing papers that are not submitted to the most appropriate venues".
== Effects upon US public opinion == One effect of the dispute in the US was to awaken the public's interest in the issue. This interest was not wholly unsympathetic to the EU. In 1989, for example, the Consumer Federation of America and the Center for Science in the Public Interest both pressed for an adoption of a ban within the US similar to that within the EU. In a study done in 2002, 85% of respondents wanted mandatory labeling on beef produced with growth hormones.
==== Harley ==== Ricky Legere fights a bully named Harley, to defend a French kid. The bully only taps out one time in the first round, and stands through the second one, leaving the bully with $9000.
Sources: en.wikipedia.org
Dry powder is normally held at -20 °C or lower, away from light and moisture. Sealed vials can also be kept at 2-8 °C for shorter intervals. Warming to room temperature before opening prevents condensation.
In solution, hydrolysis of peptide bonds and oxidation of the methionine residue are the principal concerns. Oxidation converts methionine to its sulfoxide form, shifting the mass by sixteen daltons. Both processes are slowed by cold storage and by avoiding alkaline conditions.
A certificate documents what the supplier measured on a specific lot, not how a laboratory will use the material. Independent verification of identity and purity is common practice. Acceptance criteria should be defined before a batch is ordered.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.